Search

Your search keyword '"Rimner A"' showing total 2,107 results

Search Constraints

Start Over You searched for: Author "Rimner A" Remove constraint Author: "Rimner A"
2,107 results on '"Rimner A"'

Search Results

201. CT Radiomic Features for Predicting Resectability and TNM Staging in Thymic Epithelial Tumors

206. Predicting cancer relapse following lung stereotactic radiotherapy: an external validation study using real-world evidence.

213. AB013. Treatment of thymic oligometastastic or oligoprogressive lesions with hypofractionated radiation therapy or stereotactic body radiation therapy

214. Final Analysis of Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression Trial - A Randomized Study of Stereotactic Body Radiotherapy for Oligoprogressive Metastatic Lung and Breast Cancers

216. Impact of TMB, PD-L1 expression, and pneumonitis on outcomes to chemoradiation and durvalumab in unresectable stage III non-small cell lung cancers

217. Tumor Mutational Burden Predicts Progression-Free Survival and Local-Regional Control in Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Chemoradiation and Durvalumab

218. Biomarkers Associated with Pulmonary Exacerbations in a Prospective, Placebo-Controlled, Randomized Trial of Nintedanib for the Treatment of Radiation Pneumonitis

220. The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study

221. CNS Outcomes in ALK Fusion Positive NSCLC Patients with BM Who Received Alectinib with or without Local Therapy

225. BIOM-01. GENOMIC ALTERATIONS IN ALK FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH BRAIN METASTASES

226. Stereotactic Body Radiotherapy for Sarcoma Pulmonary Metastases

227. Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With ALK/ROS1/RET-Rearranged Lung Cancers

228. Impact of TMB, PD-L1 expression, and pneumonitis on outcomes to chemoradiation and durvalumab in unresectable stage III non-small cell lung cancers

229. Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With ALK/ROS1/RET-Rearranged Lung Cancers

235. Four-Dimensional Computed Tomography-Based Correlation of Respiratory Motion of Lung Tumors With Implanted Fiducials and an External Surrogate

236. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study

239. Identifying predictive factors for treatment failure in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy

241. EP07.01-018 Phase III Randomized Trial on Surgery, Chemo and Pleural Radiation (IMPRINT) for Resectable Pleural Mesothelioma (NRG LU-006)

244. EP05.01-025 Planned Interim Analysis of a Phase II Trial of Concurrent Durvalumab and Radiation Therapy for Locally Advanced Lung Cancer

245. EP05.01-014 Circulating Tumor DNA to Identify Genomic Biomarkers of Radiation Sensitivity in Locally Advanced Non-Small Cell Lung Cancer

246. Tumor volume as a predictor of cell free DNA mutation detection in advanced non-small cell lung cancer

247. Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer

Catalog

Books, media, physical & digital resources